Effect of piboserod, a 5-HT4 serotonin receptor antagonist, on left ventricular function in patients with symptomatic heart failure

John K Kjekshus; Christian Torp-Pedersen; Lars Gullestad; Lars Køber; Thor Edvardsen; Inge C Olsen; Ivar Sjaastad; Eirik Qvigstad; Tor Skomedal; Jan-Bjørn Osnes; Finn Olav Levy; John K Kjekshus; Christian Torp-Pedersen; Lars Gullestad; Lars Køber; Thor Edvardsen; Inge Olsen; Ivar Sjaastad; Eirik Qvigstad; Tor Skomedal; Jan-Bjørn Osnes; Finn Olav Levy

doi:10.1093/eurjhf/hfp087

Effect of piboserod, a 5-HT4 serotonin receptor antagonist, on left ventricular function in patients with symptomatic heart failure

John K Kjekshus, Christian Torp-Pedersen, Lars Gullestad, Lars Køber, Thor Edvardsen, Inge C Olsen, Ivar Sjaastad, Eirik Qvigstad, Tor Skomedal, Jan-Bjørn Osnes, Finn Olav Levy, John K Kjekshus, Christian Torp-Pedersen, Lars Gullestad, Lars Køber, Thor Edvardsen, Inge Olsen, Ivar Sjaastad, Eirik Qvigstad, Tor SkomedalJan-Bjørn Osnes, Finn Olav Levy

18 Citations (Scopus)

Abstract

AIMS: Myocardial 5-HT(4) serotonin (5-HT) receptors are increased and activated in heart failure (HF). Blockade of 5-HT(4) receptors reduced left ventricular (LV) remodelling in HF rats. We evaluated the effect of piboserod, a potent, selective, 5-HT(4) serotonin receptor antagonist, on LV function in patients with HF. METHODS AND RESULTS: This was a prospective, double-blind, parallel group trial in patients with NYHA class II-IV HF and LV ejection fraction (EF) < or =0.35. Patients receiving standard HF treatment were randomized to placebo (n = 70) or piboserod 80 mg (n = 67) for 24 weeks including 4 weeks up titration. The primary endpoint was LVEF measured by cardiac magnetic resonance imaging (MRI). Secondary endpoints were LV volumes, N-terminal pro-brain natriuretic peptide, norepinephrine, quality of life, and 6 min walk test. Piboserod significantly increased LVEF by 1.7% vs. placebo (CI 0.3, 3.2, P = 0.020), primarily through reduced end-systolic volume from 165 to 158 mL (P = 0.060). There was a trend for greater increase in LVEF (2.7%, CI -1.1, 6.6, P = 0.15) in a small subset of patients not on chronic beta-blocker therapy. There was no significant effect on neurohormones, quality of life, or exercise tolerance. Patients on piboserod reported more adverse events, but numbers were too small to identify specific safety issues. CONCLUSION: Although patients with chronic HF had a small but significant improvement in LVEF when treated with piboserod for 24 weeks, the result was not reflected in significant changes in other efficacy parameters, and its clinical relevance remains uncertain.

Original language	English
Journal	European Journal of Heart Failure
Volume	11
Issue number	8
Pages (from-to)	771-8
Number of pages	8
ISSN	1388-9842
DOIs	https://doi.org/10.1093/eurjhf/hfp087 https://doi.org/10.1093/eurjhf/hfp087
Publication status	Published - 1 Aug 2009

Access to Document

Cite this

Kjekshus, J. K., Torp-Pedersen, C., Gullestad, L., Køber, L., Edvardsen, T., Olsen, I. C., Sjaastad, I., Qvigstad, E., Skomedal, T., Osnes, J-B., Levy, F. O., Kjekshus, J. K., Torp-Pedersen, C., Gullestad, L., Køber, L., Edvardsen, T., Olsen, I., Sjaastad, I., Qvigstad, E., ... Levy, F. O. (2009). Effect of piboserod, a 5-HT4 serotonin receptor antagonist, on left ventricular function in patients with symptomatic heart failure. European Journal of Heart Failure, 11(8), 771-8. https://doi.org/10.1093/eurjhf/hfp087, https://doi.org/10.1093/eurjhf/hfp087

Kjekshus, JK, Torp-Pedersen, C, Gullestad, L, Køber, L, Edvardsen, T, Olsen, IC, Sjaastad, I, Qvigstad, E, Skomedal, T, Osnes, J-B, Levy, FO, Kjekshus, JK, Torp-Pedersen, C, Gullestad, L, Køber, L, Edvardsen, T, Olsen, I, Sjaastad, I, Qvigstad, E, Skomedal, T, Osnes, J-B & Levy, FO 2009, 'Effect of piboserod, a 5-HT4 serotonin receptor antagonist, on left ventricular function in patients with symptomatic heart failure', European Journal of Heart Failure, vol. 11, no. 8, pp. 771-8. https://doi.org/10.1093/eurjhf/hfp087, https://doi.org/10.1093/eurjhf/hfp087

@article{c40ec250117d11df803f000ea68e967b,

title = "Effect of piboserod, a 5-HT4 serotonin receptor antagonist, on left ventricular function in patients with symptomatic heart failure",

abstract = "AIMS: Myocardial 5-HT(4) serotonin (5-HT) receptors are increased and activated in heart failure (HF). Blockade of 5-HT(4) receptors reduced left ventricular (LV) remodelling in HF rats. We evaluated the effect of piboserod, a potent, selective, 5-HT(4) serotonin receptor antagonist, on LV function in patients with HF. METHODS AND RESULTS: This was a prospective, double-blind, parallel group trial in patients with NYHA class II-IV HF and LV ejection fraction (EF) < or =0.35. Patients receiving standard HF treatment were randomized to placebo (n = 70) or piboserod 80 mg (n = 67) for 24 weeks including 4 weeks up titration. The primary endpoint was LVEF measured by cardiac magnetic resonance imaging (MRI). Secondary endpoints were LV volumes, N-terminal pro-brain natriuretic peptide, norepinephrine, quality of life, and 6 min walk test. Piboserod significantly increased LVEF by 1.7% vs. placebo (CI 0.3, 3.2, P = 0.020), primarily through reduced end-systolic volume from 165 to 158 mL (P = 0.060). There was a trend for greater increase in LVEF (2.7%, CI -1.1, 6.6, P = 0.15) in a small subset of patients not on chronic beta-blocker therapy. There was no significant effect on neurohormones, quality of life, or exercise tolerance. Patients on piboserod reported more adverse events, but numbers were too small to identify specific safety issues. CONCLUSION: Although patients with chronic HF had a small but significant improvement in LVEF when treated with piboserod for 24 weeks, the result was not reflected in significant changes in other efficacy parameters, and its clinical relevance remains uncertain.",

author = "Kjekshus, {John K} and Christian Torp-Pedersen and Lars Gullestad and Lars K{\o}ber and Thor Edvardsen and Olsen, {Inge C} and Ivar Sjaastad and Eirik Qvigstad and Tor Skomedal and Jan-Bj{\o}rn Osnes and Levy, {Finn Olav} and Kjekshus, {John K} and Christian Torp-Pedersen and Lars Gullestad and Lars K{\o}ber and Thor Edvardsen and Inge Olsen and Ivar Sjaastad and Eirik Qvigstad and Tor Skomedal and Jan-Bj{\o}rn Osnes and Levy, {Finn Olav}",

year = "2009",

month = aug,

day = "1",

doi = "10.1093/eurjhf/hfp087",

language = "English",

volume = "11",

pages = "771--8",

journal = "European Journal of Heart Failure, Supplement",

issn = "1567-4215",

publisher = "JohnWiley & Sons Ltd",

number = "8",

}

TY - JOUR

T1 - Effect of piboserod, a 5-HT4 serotonin receptor antagonist, on left ventricular function in patients with symptomatic heart failure

AU - Kjekshus, John K

AU - Torp-Pedersen, Christian

AU - Gullestad, Lars

AU - Køber, Lars

AU - Edvardsen, Thor

AU - Olsen, Inge C

AU - Sjaastad, Ivar

AU - Qvigstad, Eirik

AU - Skomedal, Tor

AU - Osnes, Jan-Bjørn

AU - Levy, Finn Olav

AU - Kjekshus, John K

AU - Torp-Pedersen, Christian

AU - Gullestad, Lars

AU - Køber, Lars

AU - Edvardsen, Thor

AU - Olsen, Inge

AU - Sjaastad, Ivar

AU - Qvigstad, Eirik

AU - Skomedal, Tor

AU - Osnes, Jan-Bjørn

AU - Levy, Finn Olav

PY - 2009/8/1

Y1 - 2009/8/1

N2 - AIMS: Myocardial 5-HT(4) serotonin (5-HT) receptors are increased and activated in heart failure (HF). Blockade of 5-HT(4) receptors reduced left ventricular (LV) remodelling in HF rats. We evaluated the effect of piboserod, a potent, selective, 5-HT(4) serotonin receptor antagonist, on LV function in patients with HF. METHODS AND RESULTS: This was a prospective, double-blind, parallel group trial in patients with NYHA class II-IV HF and LV ejection fraction (EF) < or =0.35. Patients receiving standard HF treatment were randomized to placebo (n = 70) or piboserod 80 mg (n = 67) for 24 weeks including 4 weeks up titration. The primary endpoint was LVEF measured by cardiac magnetic resonance imaging (MRI). Secondary endpoints were LV volumes, N-terminal pro-brain natriuretic peptide, norepinephrine, quality of life, and 6 min walk test. Piboserod significantly increased LVEF by 1.7% vs. placebo (CI 0.3, 3.2, P = 0.020), primarily through reduced end-systolic volume from 165 to 158 mL (P = 0.060). There was a trend for greater increase in LVEF (2.7%, CI -1.1, 6.6, P = 0.15) in a small subset of patients not on chronic beta-blocker therapy. There was no significant effect on neurohormones, quality of life, or exercise tolerance. Patients on piboserod reported more adverse events, but numbers were too small to identify specific safety issues. CONCLUSION: Although patients with chronic HF had a small but significant improvement in LVEF when treated with piboserod for 24 weeks, the result was not reflected in significant changes in other efficacy parameters, and its clinical relevance remains uncertain.

AB - AIMS: Myocardial 5-HT(4) serotonin (5-HT) receptors are increased and activated in heart failure (HF). Blockade of 5-HT(4) receptors reduced left ventricular (LV) remodelling in HF rats. We evaluated the effect of piboserod, a potent, selective, 5-HT(4) serotonin receptor antagonist, on LV function in patients with HF. METHODS AND RESULTS: This was a prospective, double-blind, parallel group trial in patients with NYHA class II-IV HF and LV ejection fraction (EF) < or =0.35. Patients receiving standard HF treatment were randomized to placebo (n = 70) or piboserod 80 mg (n = 67) for 24 weeks including 4 weeks up titration. The primary endpoint was LVEF measured by cardiac magnetic resonance imaging (MRI). Secondary endpoints were LV volumes, N-terminal pro-brain natriuretic peptide, norepinephrine, quality of life, and 6 min walk test. Piboserod significantly increased LVEF by 1.7% vs. placebo (CI 0.3, 3.2, P = 0.020), primarily through reduced end-systolic volume from 165 to 158 mL (P = 0.060). There was a trend for greater increase in LVEF (2.7%, CI -1.1, 6.6, P = 0.15) in a small subset of patients not on chronic beta-blocker therapy. There was no significant effect on neurohormones, quality of life, or exercise tolerance. Patients on piboserod reported more adverse events, but numbers were too small to identify specific safety issues. CONCLUSION: Although patients with chronic HF had a small but significant improvement in LVEF when treated with piboserod for 24 weeks, the result was not reflected in significant changes in other efficacy parameters, and its clinical relevance remains uncertain.

U2 - 10.1093/eurjhf/hfp087

DO - 10.1093/eurjhf/hfp087

M3 - Journal article

C2 - 19567409

SN - 1567-4215

VL - 11

SP - 771

EP - 778

JO - European Journal of Heart Failure, Supplement

JF - European Journal of Heart Failure, Supplement

IS - 8

ER -

Effect of piboserod, a 5-HT4 serotonin receptor antagonist, on left ventricular function in patients with symptomatic heart failure

Abstract

Access to Document

Fingerprint

Cite this